Erratum: Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension (Journal of Clinical Investigation (2014) 124:8 (3514-3528) DOI: 10.1172/JCI74773);Systems-level regulation of MicroRNA networks by miR-130/301 promotes pulmonary hypertension

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3514-3528

  Bertero, Thomas ^a   Lu, Yu ^a   Annis, Sofia ^a   Hale, Andrew ^a   Bhat, Balkrishen ^b   Saggar, Rajan ^c   Saggar, Rajeev ^d   Wallace, W Dean ^c   Ross, David J ^c   Vargas, Sara O ^e   Graham, Brian B ^f   Kumar, Rahul ^f   Black, Stephen M ^g   Fratz, Sohrab ^h   Fineman, Jeffrey R ⁱ   West, James D ^j   Haley, Kathleen J ^k   Waxman, Aaron B ^k   Chau, B Nelson ^b   Cottrill, Katherine A ^a   Chan, Stephen Y ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; FIBROBLAST GROWTH FACTOR 2; MICRORNA; MICRORNA 130; MICRORNA 204; MICRORNA 301; MICRORNA 424; MICRORNA 503; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT3 PROTEIN; UNCLASSIFIED DRUG; APLN PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; MIRN130 MICRORNA, HUMAN; MIRN130 MICRORNA, MOUSE; MIRN301 MICRORNA, HUMAN; MIRN301 MICRORNA, MOUSE; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG BLOOD VESSEL; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PLASMA; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; ANOXIA; BIOLOGICAL MODEL; C57BL MOUSE; COMPLICATION; COMPUTER SIMULATION; DISEASE MODEL; GENETICS; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY; SYSTEMS THEORY; UPREGULATION;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GENE REGULATORY NETWORKS; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICRORNAS; MODELS, BIOLOGICAL; MYOCYTES, SMOOTH MUSCLE; OCTAMER TRANSCRIPTION FACTOR-3; PPAR GAMMA; PULMONARY ARTERY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYSTEMS THEORY; UP-REGULATION;

EID: 84905454459     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI161077     Document Type: Erratum

References (50)

1. Matkovich SJ, Hu Y, Dorn GW. Regulation of cardiac microRNAs by cardiac microRNAs. Circ Res. 2013;113(1):62-71.
2. Song SJ, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TETfamilydependent chromatin remodeling. Cell. 2013;154(2):311-324.
3. Shi H, et al. Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes. BMC Syst Biol. 2013;7:101.
4. Lai X, Bhattacharya A, Schmitz U, Kunz M, Vera J, Wolkenhauer O. A systems' biology approach to study microRNA-mediated gene regulatory networks. Biomed Res Int. 2013;2013:703849.
5. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol. 2013;425(19):3582-3600.
6. White K, Loscalzo J, Chan SY. Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ. 2012;2(3):278-290.
7. Courboulin A, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-548.
8. Kim J, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19(1):74-82.
9. Parikh VN, et al. MicroRNA-21 integrates pathoogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. 2012;125(12):1520-1532.
10. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
11. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105.
12. Newman ME. Modularity and community structure in networks. Proc Natl Acad Sci U S A. 2006;103(23):8577-8582.
13. Lu Z, et al. miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J. 2011;30(1):57-67.
14. Kovaleva V, et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 2012;72(7):1763-1772.
15. Hager M, et al. MicroRNA-130a-mediated downregulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors. Blood. 2011;118(25):6649-6659.
16. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that downregulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2008;111(3):1217-1226.
17. Wu WH, et al. MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension. Am J Hypertens. 2011;24(10):1087-1093.
18. Mujahid S, Nielsen HC, Volpe MV. MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One. 2013;8(2):e55911.
19. Hansmann G, et al. An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118(5):1846-1857.
20. Crossno JT, et al. Rosiglitazone attenuates hypoxiainduced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007;292(4):L885-L897.
21. Nisbet RE, et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol. 2010;42(4):482-490.
22. Liu Y, et al. Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor. Hypertension. 2012;60(6):1471-1478.
23. Rabinovitch M. PPARγ and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:447-458.
24. Alastalo TP, et al. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121(9):3735-3746.
25. Soubrier F, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D13-D21.
26. Covello KL, et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20(5):557-570.
27. Firth AL, Yao W, Remillard CV, Ogawa A, Yuan JX. Upregulation of Oct-4 isoforms in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;298(4):L548- L557.
28. Ciuclan L, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184(10):1171-1182.
29. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104(2):236-244.
30. Graham BB, et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol. 2010;177(3):1549-1561.
31. West J, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94(8):1109-1114.
32. Reddy V, et al. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation. 1995;92(3):606-613.
33. Lee EK, et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2011;31(4):626-638.
34. Obad S, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011;43(4):371-378.
35. Hansmann G, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115(10):1275-1284.
36. Hansmann G, Zamanian RT. PPARγ activation: a potential treatment for pulmonary hypertension. Sci Transl Med. 2009;1(12):12ps14.
37. Li, et al. Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-γ signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. FEBS J. 2010;277(6):1543-1550.
38. Teichert-Kuliszewska K, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98(2):209-217.
39. Sakao S, Taraseviciene-Stewart L, Lee J, Wood K, Cool C, Voelkel N. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 2005;19(9):1178-1180.
40. Wang LH, et al. Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cells. Immunity. 2004;20(2):205-218.
41. Paulin R, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123(11):1205-1215.
42. Malenfant S, et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013;3(2):278-293.
43. Lee MJ, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012;149(4):780-794.
44. Chan SY, Loscalzo J. The emerging paradigm of network medicine in the study of human disease. Circ Res. 2012;111(3):359-374.
45. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44(1):14-30.
46. Hickey MM, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010;120(3):827-839.
47. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301(5):H1798-H1809.
48. Meloche J, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2013;129(7):786-797.
49. Kang BY, Kleinhenz JM, Murphy TC, Hart CM. The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2011;301(6):L881-L891.
50. Wei C, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One. 2013;8(5):e64396.